Transaminase mutants and their applications

By genetically modifying transaminases, transaminase mutants with high activity, stability, and broad-spectrum solvent tolerance were developed, overcoming the shortcomings of existing transaminases in sitagliptin synthesis and enabling efficient, low-cost, and environmentally friendly industrial production.

CN123107950APending Publication Date: 2026-11-17ZHEJIANG CHANGHAI PHARM CO LTD +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202611362888.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-03
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing transaminases suffer from low catalytic activity, weak thermal stability, and poor tolerance to organic solvents in the synthesis of sitagliptin, which limits their application in industrial production.

Method used

By genetically engineering wild-type transaminases and introducing specific amino acid mutations, such as F113M and I117T+Y200A, transaminase mutants with high catalytic activity, stereoselectivity, and broad-spectrum organic solvent tolerance were developed. These mutants were then expressed in host cells using recombinant plasmids.

Benefits of technology

It improves the production efficiency and product quality of sitagliptin, reduces production costs, reduces environmental pollution, and provides an efficient, economical, and green industrial production solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107950A_ABST
    Figure CN123107950A_ABST
Patent Text Reader

Abstract

This invention provides a transaminase mutant and its application. The transaminase mutant includes: (a) a protein mutated from a wild-type transaminase, wherein the mutation is selected from any one or more of the following sites: F113, M52, V60, M85, G127, E115, F141, Q143, A160, T273, A275, P288, L56, D72, I117, or Y200, wherein the wild-type transaminase includes the protein shown in SEQ ID NO: 1; or (b) a protein having more than 70% identity with the amino acid sequence defined in (a) and possessing transaminase activity. This invention addresses the problems of existing transaminases having at least one of the following: low catalytic activity, weak thermal stability, or limited organic solvent tolerance, and is applicable to the field of enzyme catalysis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of enzyme catalysis, and more specifically, to a transaminase mutant and its applications. Background Technology

[0002] Sitagliptin, chemically named 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-trifluoromethyl-1,2,4-triazolo[4,3-a]pyrazine, is primarily used in the treatment of type II diabetes in its phosphate monohydrate form. Sitagliptin improves glycemic control by increasing the level of active incretins, exhibiting significant advantages such as low incidence of adverse reactions and good safety profile, thus holding a significant position in the global diabetes drug market. The sitagliptin molecule contains a key chiral amino center, namely the (3R)-3-amino structure. The construction of this chiral center is a core step in the sitagliptin synthesis route, and its stereoselectivity directly affects the efficacy and safety of the final product. Currently, the synthesis methods of sitagliptin are mainly divided into two categories: total chemical synthesis and enzymatic synthesis.

[0003] All-chemical synthesis methods typically require expensive noble metal catalysts (such as rhodium, platinum, palladium, and niobium) to carry out asymmetric hydrogenation reactions under high temperature and high pressure conditions to construct chiral centers. However, these methods have many drawbacks, such as high cost, high operational risks, difficulty in separation and purification, and environmental unfriendliness. Given the limitations of chemical synthesis methods, enzymatic synthesis, as a green, efficient, and highly selective synthetic strategy, has gradually attracted widespread attention and become a research hotspot. The key step in the enzymatic synthesis of sitagliptin is to use transaminase to catalyze an asymmetric aminotransfer reaction of the sitagliptin precursor ketone ((2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6,2,4]triazolo[4,3-a]pyrazin-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)but-2-one) to directly obtain chiral sitagliptin. Merck, in collaboration with Codexis, used the (R)-ω-transaminase ATA-117 derived from Arthrobacter sp. as a research subject. Through directed evolution strategies including computer-aided protein structure analysis, site-directed saturation mutagenesis, and whole-genome random mutagenesis, they obtained a novel transaminase that can efficiently catalyze the synthesis of sitagliptin from sitagliptin precursor ketones (Christopher K. Savile, Jacob M. Janey, Emily C. Mundorff, et al. Biocatalytic Asymmetric Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture[J]. Science, 2010, 329(5989):305-309). Compared to traditional chemical synthesis methods, the enzymatic conversion strategy can significantly improve product yield (10%–13%), increase production efficiency (53%), and reduce total waste emissions (19%). Moreover, the reaction process does not require the addition of heavy metals, exhibiting significant environmental and economic advantages.

[0004] However, existing enzymatic methods for synthesizing sitagliptin transaminases still have some shortcomings. Firstly, the enzyme source is singular and subject to patent monopolies; currently reported highly efficient transaminases mostly originate from… ArthrobacterFurthermore, mutants and similar sequences that have undergone multiple amino acid mutations are protected by patents, which restricts the further development and application of sitagliptin by other companies and institutions in the enzymatic synthesis of sitagliptin. Therefore, it is necessary to screen for and modify (R)-ω-transaminases from more sources to overcome existing technological barriers. Secondly, the enzyme activity, stability, and solvent tolerance of transaminases need to be improved. Wild-type transaminases in nature usually have extremely low or no catalytic activity for sitagliptin precursor ketones, making them difficult to apply directly to industrial production. Although some engineered transaminases have been obtained through directed evolution, their performance still has room for improvement under industrial conditions. CN112048485B discloses a transaminase derived from Aspergillus fumigatus ( Aspergillus fumigatus The patent describes an engineered transaminase peptide that, through directed evolution, enables the synthesis of sitagliptin intermediates under industrially relevant conditions. The patent states that the reported engineered transaminase achieves approximately 93% substrate (50 g / L) conversion under methanol (35% v / v) conditions. ee The value is ≥99.7%. Although the activity is high, there is still room for further improvement. In addition, the broad-spectrum tolerance to other commonly used organic solvents, as well as the specific performance data in different solvent systems, still need to be explored in depth. CN110791538A discloses a production method suitable for the enzymatic synthesis of sitagliptin phosphate. By optimizing the enzyme catalytic reaction conditions, the conversion rate of the substrate is 93.8% under the conditions of 45℃ and 50% DMSO. CN116240189A reports a transaminase mutant ATA55, which can catalyze the reaction of the substrate (2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)but-2-one to generate the target product sitagliptin. This patent screened for a mutant EcAT64 with low inhibition of organic solvents and higher enzyme activity through environmental pressure combined with genetic engineering mutation. In a 1 L reaction system, using Ec AT64 whole-cell catalysis of a 100 g / L compound, with 50% methanol as a co-solvent, resulted in a product molar yield exceeding 97% after 12 h of reaction. ee The value is greater than 99.95%. This indicates that there is still room for further optimization in the asymmetric synthesis of sitagliptin using transaminase, such as whether its performance can remain stable under higher substrate concentrations, shorter reaction times, or a wider range of organic solvent types and concentrations.

[0005] Therefore, the present invention aims to provide a solution that can overcome the above-mentioned defects of the prior art, namely, to develop a novel engineered transaminase mutant that not only has higher catalytic activity, stereoselectivity and thermal stability, but also has stronger tolerance to a variety of organic solvents, thereby further reducing the production cost of sitagliptin and improving the economic efficiency and environmental friendliness of industrial applications. Summary of the Invention

[0006] The main objective of this invention is to provide a transaminase mutant and its application, in order to solve the problem that transaminases in the prior art have at least one of the following characteristics: low catalytic activity, weak thermal stability, or limited tolerance to organic solvents.

[0007] To achieve the above objectives, according to a first aspect of the present invention, a transaminase mutant is provided, the transaminase mutant comprising: (a) a protein mutated based on a wild-type transaminase, wherein the mutation is selected from mutations at any one or more of the following sites: F113, M52, V60, M85, G127, E115, F141, Q143, A160, T273, A275, P288, L56, D72, I117, or Y200, wherein the wild-type transaminase comprises the protein shown in SEQ ID NO: 1; or (b) a protein having more than 70% identity with the amino acid sequence defined in (a) and having transaminase activity.

[0008] Further, in (a) above, the mutation is selected from any one or more of the following mutations: F113M, M52C, V60L, M85S, G127A, E115I, F141V, Q143C, A160F, T273S, A275L, P288M, L56I, D72F, I117T or Y200A, wherein the letter before the number represents the original amino acid and the letter after the number represents the mutated amino acid.

[0009] Furthermore, the above mutations include any one of the following amino acid mutations: F113M, F113M+G127A, F113M+A160F, F113M+I117T+Y200A, L56I+D72F, I117T+Y200A, G127A+A160F, G127A+I117T+Y200A, A160F+I117T+Y200A, M52C, V60L, M85S, G127A, E115I, F141V, Q143C, A160F, T273S, A275L, P288M, L56I, D72F, I117T, or Y200A.

[0010] To achieve the above objectives, according to a second aspect of the present invention, a mutant library is provided, the mutant library comprising one or more of the following mutants: F113M, F113M+G127A, F113M+A160F, F113M+I117T+Y200A, L56I+D72F, I117T+Y200A, G127A+A160F, G127A+I117T+Y200A, A160F+I117T+Y200A, M52C, V60L, M85S, G127A, E115I, F141V, Q143C, A160F, T273S, A275L, P288M, L56I, D72F, I117T, or Y200A.

[0011] To achieve the above objectives, according to a third aspect of the present invention, a DNA molecule is provided that encodes the above-mentioned transaminase mutant or the above-mentioned mutant library.

[0012] To achieve the above objectives, according to a fourth aspect of the present invention, a recombinant plasmid is provided, the recombinant plasmid containing the aforementioned DNA molecule.

[0013] Furthermore, the aforementioned recombinant plasmid includes pET-28a.

[0014] To achieve the above objectives, according to a fifth aspect of the present invention, a host cell is provided, wherein the host cell contains the aforementioned DNA molecule or the aforementioned recombinant plasmid.

[0015] Furthermore, the aforementioned host cells include one or more of Escherichia coli, Bacillus subtilis, Pichia pastoris, or Saccharomyces cerevisiae.

[0016] To achieve the above objectives, according to a sixth aspect of the present invention, a method for preparing sitagliptin is provided, the method comprising: using the above-mentioned transaminase mutant or the above-mentioned mutant library to perform an asymmetric aminotransfer reaction on sitagliptin precursor ketone to prepare sitagliptin.

[0017] To achieve the above objectives, according to a seventh aspect of the present invention, the application of the above-described transaminase mutant, the above-described mutant library, the above-described DNA molecule, the above-described recombinant plasmid, the above-described host cell, or the above-described method for preparing sitagliptin in sitagliptin synthesis is provided.

[0018] By applying the technical solution of this invention and utilizing the aforementioned transaminase mutant, an efficient asymmetric aminotransfer reaction of sitagliptin precursor ketone can be achieved, resulting in the better preparation of sitagliptin. Compared to the wild-type enzyme, the aforementioned transaminase mutant exhibits superior catalytic performance in the asymmetric synthesis of sitagliptin, including at least one of the following advantages: high activity, high stereoselectivity, excellent thermal stability, and broad-spectrum organic solvent tolerance. The enzyme-catalyzed method provided by this invention not only significantly improves the production efficiency and product quality of sitagliptin but also substantially reduces production costs and environmental pollution, providing an efficient, economical, and green technical solution for the industrial production of sitagliptin, and has broad practical application prospects. Attached Figure Description

[0019] The accompanying drawings, which form part of this application, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. In the drawings:

[0020] Figure 1 The image shows the SDS-PAGE electrophoresis results of wild-type transaminase according to Example 4 of the present invention.

[0021] Figure 2 The HPLC chromatogram of sitagliptin precursor ketone according to Example 6 of the present invention is shown.

[0022] Figure 3 The HPLC chromatogram of sitagliptin according to Example 6 of the present invention is shown. Detailed Implementation

[0023] It should be noted that, unless otherwise specified, the embodiments and features described in this application can be combined with each other. The present invention will now be described in detail with reference to the embodiments.

[0024] In this application, unless otherwise expressly stated, the technical and scientific terms used herein shall have the meanings commonly understood by one of ordinary skill in the art.

[0025] Sitagliptin precursor ketone: refers to compounds with the chemical structure (2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)but-2-one, which is the substrate for the enzyme-catalyzed reaction of this invention.

[0026] Sitagliptin: refers to the compound with the chemical structure 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-trifluoromethyl-1,2,4-triazolo[4,3-a]pyrazine, which is the target product of the enzyme-catalyzed reaction of this invention.

[0027] Transaminase: refers to enzymes that can catalyze aminotransfer reactions, including wild-type transaminases and engineered transaminase mutants.

[0028] Transaminase mutants: These are transaminases whose amino acid sequences have been modified (including but not limited to substitution, insertion, and deletion) through genetic engineering, thereby improving their catalytic activity, stereoselectivity, thermal stability, solvent tolerance, and other properties.

[0029] Wild-type transaminase: refers to transaminase that exists in nature and has not been artificially modified. In this application, the amino acid sequence of the wild-type transaminase is shown in SEQ ID NO: 1.

[0030] Amino acid sequence: refers to a polypeptide chain composed of amino acid residues linked together by peptide bonds.

[0031] Nucleotide sequence: refers to a polynucleotide chain composed of nucleotides linked by phosphodiester bonds, including DNA and RNA.

[0032] Gene: refers to a nucleic acid sequence that encodes a specific protein or has a specific function.

[0033] Recombinant expression vectors: These are vectors that can introduce foreign genes into host cells and enable them to be expressed, such as plasmids, bacteriophages, and viral vectors.

[0034] Host cell: refers to a cell that can receive recombinant expression vectors and express foreign genes, such as bacteria, yeast, fungi, plant cells or animal cells.

[0035] Asymmetric synthesis: refers to a synthetic method that can generate specific chiral isomers with high selectivity in a chemical reaction.

[0036] Stereoselectivity refers to the preferential formation of one stereoisomer relative to one or more other isomers in a chemical or enzymatic reaction. When the stereoisomers are enantiomers, stereoselectivity is called enantiomer selectivity, usually expressed as enantiomer excess (…). ee (Value) is used to represent this.

[0037] Catalytic activity refers to the efficiency of an enzyme in catalyzing the conversion of a substrate into a product. It is usually measured by substrate conversion rate, product formation rate, or the amount of substrate converted per unit time.

[0038] Thermal stability: refers to the ability of an enzyme to maintain its catalytic activity at higher temperatures.

[0039] Solvent tolerance: refers to the ability of an enzyme to maintain its catalytic activity in a reaction system containing organic solvents.

[0040] Coenzymes are non-protein organic molecules that bind to enzymes and participate in catalytic reactions, such as pyridoxal phosphate (PLP).

[0041] Amino donor: refers to a compound that provides an amino group in an amino transfer reaction, such as isopropylamine and o-phenylenediamine dihydrochloride.

[0042] Codon optimization: refers to the technique of modifying the nucleotide sequence of a gene according to the codon preference of a specific host cell in order to improve the efficiency of protein expression.

[0043] As mentioned in the background section, existing technologies suffer from problems such as low catalytic activity, poor stereoselectivity, weak thermal stability, and poor tolerance to organic solvents in transaminases. Therefore, in this application, the inventors attempt to provide the aforementioned transaminase mutant, which can achieve efficient asymmetric aminotransfer reaction of sitagliptin precursor ketone, thus better preparing sitagliptin. Compared to the wild-type enzyme, the aforementioned transaminase mutant exhibits superior catalytic performance in the asymmetric synthesis of sitagliptin, including at least one of the following: high activity, high stereoselectivity, excellent thermal stability, and broad-spectrum tolerance to organic solvents. Therefore, a series of protection schemes are proposed in this application.

[0044] In a first typical embodiment of this application, a transaminase mutant is provided, the transaminase mutant comprising: (a) a protein mutated based on a wild-type transaminase, wherein the mutation is selected from mutations at any one or more of the following sites: F113, M52, V60, M85, G127, E115, F141, Q143, A160, T273, A275, P288, L56, D72, I117, or Y200, wherein the wild-type transaminase comprises the protein shown in SEQ ID NO: 1; or (b) a protein having more than 70% identity with the amino acid sequence defined in (a) and having transaminase activity.

[0045] In a preferred embodiment, in (a) above, the mutation is selected from any one or more of the following mutations: F113M, M52C, V60L, M85S, G127A, E115I, F141V, Q143C, A160F, T273S, A275L, P288M, L56I, D72F, I117T or Y200A, wherein the letter before the number represents the original amino acid and the letter after the number represents the mutated amino acid.

[0046] By performing any one or more of the aforementioned transaminase mutants, transaminase mutants can be prepared. These prepared transaminase mutants are better suited for the preparation of target products, including but not limited to sitagliptin, compared to wild-type transaminases. Compared to wild-type enzymes, these transaminase mutants significantly improve the production efficiency and product quality of sitagliptin, while also substantially reducing production costs and environmental pollution. This provides an efficient, economical, and green technical solution for the industrial production of sitagliptin, and has broad practical application prospects.

[0047] It should be noted that the mutation numbering in this application is based on the wild-type transaminase shown in SEQ ID NO: 1.

[0048] In a preferred embodiment, the above mutation includes any one of the following amino acid mutations: F113M, F113M+G127A, F113M+A160F, F113M+I117T+Y200A, L56I+D72F, I117T+Y200A, G127A+A160F, G127A+I117T+Y200A, A160F+I117T+Y200A, M52C, V60L, M85S, G127A, E115I, F141V, Q143C, A160F, T273S, A275L, P288M, L56I, D72F, I117T, or Y200A.

[0049] In two typical embodiments of this application, a mutant library is provided, which includes, but is not limited to, one or more of the following mutants: F113M, F113M+G127A, F113M+A160F, F113M+I117T+Y200A, L56I+D72F, I117T+Y200A, G127A+A160F, G127A+I117T+Y200A, A160F+I117T+Y200A, M52C, V60L, M85S, G127A, E115I, F141V, Q143C, A160F, T273S, A275L, P288M, L56I, D72F, I117T, or Y200A.

[0050] SEQ ID NO: 1:

[0051] MATMDKVFAGYAARQAVLEASTNPFAKGIAWVEGELVPLHEARIPLLDQGFMHSDLTYDVPSVWDGRFFRLDDHLDRLEASCKKMRLRLPLPRDEVKQILVDMVAKSGIRDAFVELIVTRGLTGVRGARPEELLKNNLYMFVQPYVWVMEPEVQRAGGSA IVARTVRRIPPGSIDPTIKNLQWGDLVRGLFEASDRGATYPFLTDGDANLTEGSGFNIVLVKDGVLYTPDRGVLQGITRKSVIDAAKACGFEIRVEFVPVELAYQADEIFMCTTAGGIMPITTLDGKPVNDGKVGPITKKIWDRYWAMHYDDEYSFEIDY.

[0052] In this application, "+" means "and", for example, "F113M+G127A" means that the F113M mutation and the G127A mutation occur simultaneously on the basis of the transaminase shown in SEQ ID NO: 1.

[0053] In a preferred embodiment, the transaminase mutant comprises a protein having 80% or more, 85% or more, more preferably 95% or more, and even more preferably 99% or more identity with the amino acid sequence defined in (a) and having transaminase activity.

[0054] All the aforementioned amino acid mutations were experimentally investigated in the embodiments of this application. Compared to the parent protein with the amino acid sequence shown in SEQ ID NO: 1, all mutations exhibited the activity of hydrolyzing sitagliptin precursor ketone to obtain sitagliptin. The mutation sites were all located around the active amino acid site, which improved the binding affinity and / or catalytic activity of the mutant to the substrate. Mutations located far from the active site had less impact on the enzyme's catalytic activity, thus enabling the production of proteins with 80% or more identity to the aforementioned amino acid sequence and identical catalytic activity.

[0055] In this application, identity refers to the total ratio of the same type of amino acid residues in the amino acid sequence. Amino acid sequence identity can be determined using alignment programs such as BLAST (Basic Local Alignment Search Tool) and FASTA.

[0056] Proteins with 70%, 75%, 80%, 85%, 90%, 95%, or more than 99% (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or even more than 99.9%) are homologous and have the same function. Their active sites, active pockets, active mechanisms, and protein structures are likely to be the same as the protein provided by sequence (a). They are homologous proteins obtained through amino acid mutation.

[0057] As used herein, the amino acid residue abbreviations are as follows: Glycine (Gly; G), Alanine (Ala; A), Valine (V), Leucine (L), Isoleucine (Ile; I), Proline (Pro; P), Methionine (Met; M), Serine (Ser; S), Cysteine ​​(Cys; C), Threonine (Threonine; Thr; T), Asparagine (Asn; N), Glutamine (Gln; Q), Phenylalanine (Phe; F), Tyrosine (Tyr; Y), Tryptophan (Trp; W), Aspartic acid (Asp; D), Glutamic acid (Glu; E), Lysine (Lys; K), Arginine (Arg; R), Histidine (Histidine; His; H).

[0058] The main principle of mutant substitution in this invention is: substitution between amino acids with similar properties, including but not limited to:

[0059] Intersubstitution between nonpolar or hydrophobic amino acids (G, A, V, L, I, P, M);

[0060] Intersubstitution between hydrophobic aromatic amino acids (F, Y, W);

[0061] Amino acids (K, R, H) with positively charged side chains substitute for each other;

[0062] The negatively charged amino acids (D and E) in the side chains substitute for each other;

[0063] Intersubstitution between polar, neutral, or hydrophilic amino acids (S, C, T, N, Q);

[0064] Amino acid substitutions between protein sequences that have more than 70% identity with the amino acid sequence of SEQ ID NO: 1.

[0065] Those skilled in the art can also perform conservative substitutions of amino acids based on amino acid substitution rules well known to them, such as the "blosum62 score matrix" in the prior art.

[0066] The "AlphaFold2-Multimer" used in this application is a publicly available artificial intelligence model capable of predicting the conformation of protein complexes. Its predictions of protein three-dimensional structures are very close to those observed in real-world experiments using equipment such as cryo-electron microscopy. This allows for the acquisition of relatively realistic protein structures, thereby guiding the investigation of protein structure and activity.

[0067] In a preferred embodiment, the above-mentioned transaminase mutant has been mutated at the following sites relative to the amino acid sequence of the wild-type transaminase (amino acid sequence as shown in SEQ ID NO: 1): the amino acid Phe at position 113 is replaced with Met, the amino acid Ile at position 117 is replaced with Thr, and the amino acid Tyr at position 200 is replaced with Ala, and the amino acid sequence after that is shown in SEQ ID NO: 2.

[0068] SEQ ID NO: 2:

[0069] MATMDKVFAGYAARQAVLEASTNPFAKGIAWVEGELVPLHEARIPLLDQGFMHSDLTYDVPSVWDGRFFRLDDHLDRLEASCKKMRLRLPLPRDEVKQILVDMVAKSGIRDAMVELTVTRGLTGVRGARPEELLKNNLYMFVQPYVWVMEPEVQRAGGSA IVARTVRRIPPGSIDPTIKNLQWGDLVRGLFEASDRGATAPFLTDGDANLTEGSGFNIVLVKDGVLYTPDRGVLQGITRKSVIDAAKACGFEIRVEFVPVELAYQADEIFMCTTAGGIMPITTLDGKPVNDGKVGPITKKIWDRYWAMHYDDEYSFEIDY.

[0070] In a preferred embodiment, the nucleotide sequence of the gene encoding the above-mentioned wild-type transaminase is shown in SEQ ID NO: 3.

[0071] In a preferred embodiment, the above-mentioned transaminase mutant has a mutation at the following sites relative to the amino acid sequence of the wild-type transaminase (amino acid sequence as shown in SEQ ID NO: 1): the amino acid Phe at position 113 is replaced with Met, the amino acid Ile at position 117 is replaced with Thr, and the amino acid Tyr at position 200 is replaced with Ala. The nucleotide sequence of the gene encoding the above-mentioned transaminase mutant is shown in SEQ ID NO: 4.

[0072] SEQ ID NO: 3:

[0073] atggccacgatggataaagtctttgccggttatgcagccagacaagcagttttagaagcaagtaccaatcctttcgcaaaaggtatcgcatgggtagaaggagaattagtaccactacatgaagcccgaatccctttattagatcaaggctttatgcatagtgatctcacgtatgacgttccgtctgtctgggatggccgtttctttcgtctggatgatcaccttgaccgcctggaagcctcatgcaaaaagatgcgcctgcgtctcccactgccacgggatgaggtgaaacagatccttgtggatatggtcgcgaaatccggcattcgtgacgcgttcgtggagctgattgtgacccgtggtcttacgggagtgagaggtgcgcgaccggaggaactgctaaagaacaacctgtacatgtttgttcagccgtatgtatgggttatggagccggaagtacagcgtgctggcggctcggctattgtggcacgtactgtccgccgcattccacctggcagcatcgacccaaccattaaaaatctgcagtggggtgacctggtgcgtggattgtttgaagcgtctgatcgtggcgcgacctatccgtttctaaccgatggcgacgcaaacttgactgaaggctctggctttaacattgtactggtgaaagacggtgtcctgtacacaccggatcgcggcgtgctgcagggtattacccgcaagagcgtgatcgatgcggccaaagcatgcggcttcgaaattcgcgttgaatttgtgccggtcgaactggcataccaagcggacgaaatcttcatgtgtacaaccgcgggtggcattatgccgatcaccaccctggatgggaaacctgtgaacgatggaaaagtaggaccgattacgaagaaaatatgggatagatactgggcaatgcattatgacgatgaatacagttttgaaattgattattaa。

[0074] In a preferred embodiment, the nucleotide sequence of the above-mentioned gene is obtained by substituting the codons encoding the corresponding amino acids based on the nucleotide sequence shown in SEQ ID NO: 3. Those skilled in the art can obtain the above-mentioned coding gene through artificial synthesis or through site-directed mutagenesis.

[0075] SEQ ID NO: 4:

[0076] atggccacgatggataaagtctttgccggttatgcagccagacaagcagttttagaagcaagtaccaatcctttcgcaaaaggtatcgcatgggtagaaggagaattagtaccactacatgaagcccgaatccctttattagatcaaggctttatgcatagtgatctcacgtatgacgttccgtctgtctgggatggccgtttctttcgtctggatgatcaccttgaccgcctggaagcctcatgcaaaaagatgcgcctgcgtctcccactgccacgggatgaggtgaaacagatccttgtggatatggtcgcgaaatccggcattcgtgacgcgatggtggagctgaccgtgacccgtggtcttacgggagtgagaggtgcgcgaccggaggaactgctaaagaacaacctgtacatgtttgttcagccgtatgtatgggttatggagccggaagtacagcgtgctggcggctcggctattgtggcacgtactgtccgccgcattccacctggcagcatcgacccaaccattaaaaatctgcagtggggtgacctggtgcgtggattgtttgaagcgtctgatcgtggcgcgaccgcaccgtttctaaccgatggcgacgcaaacttgactgaaggctctggctttaacattgtactggtgaaagacggtgtcctgtacacaccggatcgcggcgtgctgcagggtattacccgcaagagcgtgatcgatgcggccaaagcatgcggcttcgaaattcgcgttgaatttgtgccggtcgaactggcataccaagcggacgaaatcttcatgtgtacaaccgcgggtggcattatgccgatcaccaccctggatgggaaacctgtgaacgatggaaaagtaggaccgattacgaagaaaatatgggatagatactgggcaatgcattatgacgatgaatacagttttgaaattgattattaa。

[0077] In a third typical embodiment of this application, a DNA molecule is provided that encodes the transaminase mutant or the mutant library described above.

[0078] In a fourth typical embodiment of this application, a recombinant plasmid is provided, the recombinant plasmid containing the aforementioned DNA molecule.

[0079] In a preferred embodiment, the recombinant plasmid described above includes pET-28a.

[0080] The aforementioned DNA can encode the aforementioned transaminase mutant and can be ligated to a recombinant plasmid to form a circular DNA. Both the aforementioned DNA and the recombinant plasmid can be transcribed and translated under the action of RNA polymerase, ribosomes, tRNA, etc., to obtain the aforementioned transaminase mutant. In this application, the inventors preferably selected pET-28a as the recombinant plasmid used in the experiment.

[0081] In a fifth typical embodiment of this application, a host cell is provided, wherein the host cell contains the aforementioned DNA molecule or the aforementioned recombinant plasmid.

[0082] In a preferred embodiment, the host cell includes one or more of Escherichia coli, Bacillus subtilis, Pichia pastoris, or Saccharomyces cerevisiae.

[0083] In a preferred embodiment, the host cell includes Escherichia coli BL21(DE3).

[0084] Using the aforementioned host cells, recombinant plasmids can be replicated within the host cells, and the DNA molecules carried on the recombinant plasmids can be transcribed and translated to obtain a large number of transaminase mutants. Using existing technologies, transaminase mutants can be obtained by cleaving and purifying proteins from host cells, including but not limited to *Escherichia coli*, *Bacillus subtilis*, *Pichia pastoris*, *Saccharomyces cerevisiae*, or *Saccharomyces cerevisiae*, followed by crude enzyme catalysis or other methods. In this application, the inventors preferably selected *Escherichia coli* BL21(DE3) as the host cell used in the experiments.

[0085] In a sixth typical embodiment of this application, a method for preparing sitagliptin is provided, the method comprising: using the transaminase mutant or the mutant library described above to perform an asymmetric aminotransfer reaction on sitagliptin precursor ketone to prepare sitagliptin.

[0086] In a preferred embodiment, the system for the above-described asymmetric amino transfer reaction further contains one or more of a cosolvent, an amino donor, or a coenzyme.

[0087] In a preferred embodiment, the co-solvent comprises an organic solvent.

[0088] In a preferred embodiment, the organic solvent comprises one or more of methanol, ethanol, propanol, isopropanol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), isopropyl acetate, ethyl acetate, 1-octanol, methyl tert-butyl ether (MTBE), or toluene; preferably, in the system of the asymmetric amino transfer reaction, the volume percentage of the organic solvent comprises 10%.

[0089] In a preferred embodiment, the organic solvent is methanol; preferably, in the system of the asymmetric amino transfer reaction, the volume percentage of methanol is 1-100% (including but not limited to 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%); more preferably, the volume percentage of methanol is 10-60% (10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or 60%); and even more preferably, the volume percentage of methanol is 30-50% (30%, 35%, 40%, 45% or 50%).

[0090] In a preferred embodiment, the amino donor is selected from one or more of isopropylamine, o-phenylenediamine dihydrochloride, phenylalanine, glutamine, leucine, or 3-aminobutyric acid; preferably, the amino donor is isopropylamine; more preferably, in the system of the asymmetric amino transfer reaction, the concentration of the isopropylamine includes 0.1-4.0M (including but not limited to 0.1 M, 1 M, 1.5 M, 2 M, 2.5 M, 3 M, 3.5 M, or 4 M).

[0091] In a preferred embodiment, the coenzyme mentioned above includes, but is not limited to, pyridoxal phosphate (PLP); preferably, in the system of the asymmetric amino transfer reaction, the concentration of pyridoxal phosphate is 0.1-5 mM (including but not limited to 0.1 mM, 0.5 mM, 1 mM, 1.5 mM, 2 mM, 3 mM, 4 mM or 5 mM).

[0092] In a preferred embodiment, the temperature of the above-mentioned asymmetric amino transfer reaction includes 10-60°C (including but not limited to 10°C, 15°C, 20°C, 25°C, 30°C, 35°C, 40°C, 45°C, 50°C, 55°C or 60°C).

[0093] In a preferred embodiment, the pH of the above-mentioned asymmetric aminotransfer reaction includes 7-11 (including but not limited to 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5 or 11); preferably, the pH of the above-mentioned asymmetric aminotransfer reaction includes 8-9 (including but not limited to 8, 8.5 or 9); more preferably, the pH of the above-mentioned asymmetric aminotransfer reaction is 8.5.

[0094] In a preferred embodiment, in the system of the above-described asymmetric amino transfer reaction, the loading of the sitagliptin precursor ketone is 1-200 g / L (including but not limited to 1 g / L, 5 g / L, 10 g / L, 100 g / L or 200 g / L), preferably 10-100 g / L, and more preferably 50 g / L.

[0095] In a preferred embodiment, in the system of the above-described asymmetric aminotransferase reaction, the loading of the transaminase mutant is 0.1-50 g / L, preferably 5-20 g / L.

[0096] In a preferred embodiment, an enantiomer of the above-mentioned sitagliptin is in excess ( ee Value) ≥ 99.9%.

[0097] In this application, the inventors discovered that the transaminase mutant or mutant library obtained by the above preparation can effectively perform asymmetric aminotransfer reaction on sitagliptin precursor ketone to prepare sitagliptin. Compared with the wild-type enzyme, the above transaminase mutant can significantly improve the production efficiency and product quality of sitagliptin, and can also significantly reduce production costs and reduce environmental pollution. It provides an efficient, economical, and green technical solution for the industrial production of sitagliptin and has broad practical application prospects.

[0098] It should be noted that the above-mentioned reaction for preparing the target product sitagliptin can be carried out in systems including, but not limited to, aqueous systems or two-phase systems. A two-phase system refers to a system containing two physically different, separate, and coexisting phases (including, but not limited to, gas-liquid, liquid-liquid, gas-solid, or liquid-solid systems). A clear interface exists between these two phases, they can coexist, and each phase possesses relatively uniform physical and chemical properties. Liquid-liquid two-phase systems include, but are not limited to, water-oil systems or water-insoluble organic solvents (including, but not limited to, organic solvents with solubility <1 g / 100 mL at 25°C).

[0099] In a seventh typical embodiment of this application, the above-mentioned transaminase mutant, the above-mentioned mutant library, the above-mentioned DNA molecule, the above-mentioned recombinant plasmid, the above-mentioned host cell, and the above-mentioned method for preparing sitagliptin are provided for use in sitagliptin synthesis.

[0100] In this application, the inventors discovered that the above-mentioned transaminase mutant, mutant library, DNA molecule, recombinant plasmid, host cell, and sitagliptin preparation method can be well applied to the sitagliptin synthesis process. Compared with wild-type enzyme, the above-mentioned transaminase mutant can significantly improve the production efficiency and product quality of sitagliptin, and can also greatly reduce production costs and reduce environmental pollution. It provides an efficient, economical, and green technical solution for the industrial production of sitagliptin and has broad practical application prospects.

[0101] The beneficial effects of this application will be explained in more detail below with reference to specific embodiments.

[0102] Example 1: Cloning of wild-type transaminase AT165

[0103] Ancestor sequence reconstruction (ASR) was used to select bacteria from the genus *Arthrobacter* (…). Arthrobacter The amino acid sequence of the transaminase sp. KNK168 was used as a probe (Genebank accession number: BAK39753.1). The ancestral transaminase AT165 (amino acid sequence as shown in SEQ ID NO: 1) was screened using the FireProt-ASR online tool (https: / / loschmidt.chemi.muni.cz / fireprotasr / ). The coding gene (nucleotide sequence as shown in SEQ ID NO: 3) was obtained through codon optimization. The full-length sequence was artificially synthesized by a gene synthesis company. The plasmid pET-28a was selected as the expression vector and submitted to a commercial company to construct the recombinant plasmid pET-28a-AT165.

[0104] Example 2 Construction of recombinant genetically engineered strain of wild-type transaminase AT165

[0105] The constructed recombinant expression plasmid pET-28a-AT165 was introduced into *E. coli* BL21(DE3) competent cells via chemical transformation. The transformation product was plated on LB agar plates containing 50 μg / mL kanamycin and incubated overnight at 37°C. Sequencing confirmed the construction of the transaminase, thus yielding recombinant *E. coli*. E. coli BL21(DE3) / pET-28a-AT165.

[0106] Example 3: Culture and protein expression of wild-type transaminase AT165

[0107] Picking recombinant E. coli E. coli A single colony of BL21(DE3) / pET-28a-AT165 was inoculated into LB liquid medium containing kanamycin and incubated overnight at 37°C and 220 rpm with a shaker. The next day, a 1% (v / v) inoculum was transferred to LB liquid medium containing 50 μg / mL kanamycin and incubated at 37°C and 220 rpm until OD500. 600 The concentration was increased to 0.6-0.8. IPTG (isopropyl-β-D-thiogalactoside) (final concentration 0.1 mM) was added to induce protein expression, followed by induction culture at 25℃ and 220 rpm for 15-20 h.

[0108] Example 4 Preparation of crude enzyme solution and enzyme powder of wild-type transaminase AT165

[0109] After expression, the bacterial culture was centrifuged at 4°C and 8000 rpm for 10 min, and the wet bacterial cells were collected. The wet bacterial cells were resuspended in PBS buffer (pH 7.0), sonicated in an ice bath, and the supernatant was collected by centrifugation to obtain the crude enzyme solution containing the engineered transaminase mutant. The SDS-PAGE electrophoresis image of the wild-type transaminase AT165 in this application is shown below. Figure 1 As shown, Figure 1 In the diagram, M represents the marker, lane 1 represents the supernatant obtained after lysis and centrifugation, and lane 2 represents the enzyme precipitate collected after lysis and centrifugation. Figure 1 The experimental results showed that transaminase AT165 has good solubility, and the crude enzyme solution can be used directly for subsequent reactions or further purified. The crude enzyme solution was freeze-dried to obtain the engineered transaminase mutant enzyme powder. The enzyme powder can be stored at -20℃ for later use.

[0110] Example 5 Construction of transaminase AT165 mutant

[0111] A random mutation strategy was employed to improve the catalytic activity of transaminases on sitagliptinone substrates. Based on the AT165 open reading frame sequence, the forward and reverse primers were designed as follows:

[0112] Upstream primer: CGCGGATCCATGGCCACGATGGATAAAGTC (SEQ ID NO: 5).

[0113] Downstream primer: CCGCTCGAGTTAATAATCAATTTCAAAACTG (SEQ ID NO: 6).

[0114] The upstream primer used GGATCC as the BamHI restriction site, and the downstream primer used CTCGAG as the XhoI restriction site.

[0115] Using recombinant plasmid pET-28a-AT165 as a template, a random mutant library was constructed by error-prone PCR performed with rTaq DNA polymerase. The PCR reaction system is shown below: rTaq DNA polymerase 1.0 μL; 10× PCR buffer (Mg²⁺). + 5.0 μL of Plus; 4.0 μL of dNTP Mixture; 50 μM of MnCl2; 10 ng of pET-28a-AT165 plasmid; 1.5 μL each of forward and reverse primers (10 μM); and bring the remaining volume to 50 μL with sterile water.

[0116] The PCR reaction program was set as follows: (1) 95℃ pre-denaturation for 3 min; (2) 95℃ denaturation for 30 s; (3) 60℃ annealing for 30 s; (4) 72℃ extension for 100 s; steps (2) to (4) were performed for a total of 30 cycles; then the product was extended at 72℃ for 10 min and stored at 4℃.

[0117] After confirmation by agarose gel electrophoresis, the PCR products were excised and purified. The recovered target gene DNA fragment and the empty vector plasmid pET-28a were then processed with restriction endonucleases. BamH I and Xho I was double-digested with enzymes at 37℃ for 5 h. The digested products were then analyzed and verified by agarose gel electrophoresis, purified, and recovered. Subsequently, the linearized pET-28a plasmid was ligated to the purified target gene fragment using T4 DNA ligase at 16℃ overnight. The ligation product was transformed into *E. coli*. E. coli BL21(DE3) competent cells were evenly spread on LB agar plates containing 50 μg / mL kanamycin and incubated statically at 37°C for about 12 h.

[0118] Example 6: Culture and Screening of Mutants

[0119] Single colonies from the transformation plates obtained in Example 5 were picked and transferred to 96-well deep-well plates and cultured overnight at 37°C and 200 rpm. 50 μL of bacterial culture was taken from the primary plate wells and inoculated into the corresponding secondary plate wells. After culturing at 37°C and 800 rpm for 4 h, IPTG was added to a final concentration of 0.1 mM, followed by further culturing at 16°C for 20 h. After culturing, the cells were centrifuged at 3500 × g for 10 min at 4°C, the supernatant was discarded, and wet cells of each mutant strain were obtained. 200 μL of cell lysis buffer (prepared by dissolving 750 mg of lysozyme in 1 L of deionized water) was added to each well, and the cells were thoroughly mixed and lysed at 25°C and 800 rpm for 2 h. The activity of the expressed protein was detected in the 96-well plates by adding the following component: 5 g / L sitagliptin prodrug. The HPLC chromatogram is shown below. Figure 2 The reaction mixture consisted of 1.5 M isopropylamine, 0.1 mM coenzyme PLP (pyridoxal phosphate), and 10% (v / v) DMSO (dimethyl sulfoxide). The reaction solution was brought to a final volume of 500 μL with 0.1 M PBS buffer (pH 8.0). The plate was placed in a 45°C shaker and the reaction was carried out at 400 rpm for 24 h. After the reaction was complete, acetonitrile was added to terminate the reaction, and the protein precipitate was removed by centrifugation. The supernatant was analyzed by HPLC. The enzyme activity (unit of enzyme activity is defined as the amount of enzyme that converts 1 micromolar of substrate per minute under optimal conditions) was calculated by detecting the product (sitagliptin). ee Values, among which, the HPLC chromatogram of sitagliptin is as follows Figure 3 As shown in Table 1, the mutants with enhanced activity are presented.

[0120] Conversion rate was determined by HPLC using a C18 column (4.6 × 150 mm, 5 μm), a mobile phase of a mixture of ammonium acetate buffer (10 mM, pH 7.0) and acetonitrile (50:50), a flow rate of 1.0 mL / min, and a detection wavelength of 254 nm.

[0121] HPLC chiral detection ee Values: A CHIRALPAK AD-H chiral column (4.6 × 250 mm, 5 μm) was used. The mobile phase was ethanol: n-heptane: triethylamine (e.g., 60:40:0.1), the flow rate was 0.7 mL / min, the column temperature was 30℃, and the detection wavelength was 254 nm.

[0122] Table 1

[0123]

[0124] In Table 1, + indicates that the activity is approximately 1.2-1.5 times that of the wild type, and ++ indicates that the activity is 2-3 times that of the wild type.

[0125] Example 7: Combinatorial Mutation of Mutants and Determination of Their Catalytic Performance

[0126] Using the mutant plasmid DNA with significantly improved performance from Example 6 as a template, combined mutagenesis was performed, and site-directed mutagenesis PCR was conducted using the primers listed in Table 2. The PCR program was as follows: 95℃ pre-denaturation for 3 min, followed by 30 cycles (95℃ denaturation for 15 s, 60℃ annealing for 15 s, 72℃ extension for 4 min), and a final extension at 72℃ for 10 min. The PCR products were then... Dpn I (methylated template digestive enzyme) was used to treat the cells at 37 °C for 2 h, followed by transfer to *E. coli* BL21(DE3) competent cells. The cells were then plated on LB agar containing 50 μg / mL kanamycin and incubated at 37 °C inverted for 12 h. Single colonies were picked and incubated on LB agar containing 50 μg / mL kanamycin at 37 °C and 200 rpm for 12 h, followed by sequencing identification. Mutants with correct sequencing results were used to obtain wet cells according to the method in Example 6.

[0127] Table 2

[0128]

[0129] The catalytic performance of the combined mutants was determined according to the method in Example 6, and the test results are shown in Table 3.

[0130] Table 3

[0131]

[0132] In Table 3, + indicates that the activity is approximately 1.2-1.5 times that of the wild type, and +++ indicates that the activity is more than 5 times that of the wild type.

[0133] Example 8: Thermal stability study of engineered transaminase mutants

[0134] A single colony of recombinant *E. coli* F113M+I117T+Y200A containing the engineered transaminase mutant gene was used to prepare a crude enzyme solution of the engineered transaminase mutant according to the methods in Examples 3 and 4, and aliquoted into centrifuge tubes. A portion of the enzyme solution was left untreated as a control, while the other portion was heat-treated by shaking in a water bath at 30, 35, 40, 45, 50, 55, or 60°C for 1 h. After heat treatment, the enzyme solution was centrifuged at 4°C and 4000 rpm for 30 min, and the supernatant was collected. The enzyme solutions before and after heat treatment were used for catalytic reaction and catalytic performance determination according to the reaction system and conditions in Example 6. The effect of temperature on the catalytic performance of the transaminase mutant is shown in Table 4. The results show that as the treatment temperature increases, the engineered transaminase mutant still maintains high catalytic activity after heat treatment at 45°C for 1 h. The relative activity decreases slightly after the temperature exceeds 45°C, indicating that the mutant has excellent thermal stability.

[0135] Table 4

[0136]

[0137] In Table 4, the activity of the control group that did not undergo heat treatment is 100%, referring to the enzyme solution at 4°C.

[0138] Example 9: Study on the organic solvent tolerance of engineered transaminase mutants

[0139] The reaction system of Example 6 was followed, but the organic co-solvent DMSO was replaced with other organic solvents such as methanol, ethanol, propanol, isopropanol, dimethylformamide (DMF), isopropyl acetate, ethyl acetate, 1-octanol, methyl tert-butyl ether (MTBE), and toluene in equal volume percentages (10% v / v). Catalytic reactions and catalytic performance were conducted in reaction systems containing different organic solvents under the reaction conditions of Example 6, and the results are shown in Table 5. The engineered transaminase mutant of this invention maintains high catalytic activity in reaction systems containing various organic solvents such as methanol, ethanol, isopropanol, or DMSO. The highest activity is observed in methanol; even when the methanol concentration is increased to 30%, the relative activity still reaches over 93%, indicating that this mutant has broad-spectrum organic solvent tolerance.

[0140] Table 5

[0141]

[0142] In Table 5, the data for the reaction under different co-solvents are compared with the highest activity as 100%.

[0143] Example 10 High-density fermentation process of engineered transaminase mutants

[0144] A single colony of recombinant *E. coli* F113M+I117T+Y200A containing the engineered transaminase mutant gene was inoculated into 50 mL of LB broth containing kanamycin (50 μg / mL) and cultured overnight at 30°C using a shaker. The OD of the culture was... 600 When the pH reaches 1.6-2.2, the seed culture is obtained. A 5 L fermenter containing 2.0 L LB medium is autoclaved at 121°C. The fermenter is then inoculated with the seed culture.

[0145] During fermentation, the temperature was controlled at 37°C using a jacketed circulating water system, the stirring speed was 200-800 rpm, and air was introduced to maintain dissolved oxygen levels at 40% saturation or higher. Sodium hydroxide was added to maintain the pH of the culture at 7.0. Culture growth was maintained by a fed-batch solution containing 500 g / L glucose, 12 g / L ammonium chloride, and 5 g / L magnesium sulfate heptahydrate. The culture temperature was maintained at 30°C before induction of expression. Expression of the engineered transaminase mutant was induced by adding IPTG to a final concentration of 0.2 mM, and fermentation continued for approximately 18 h.

[0146] After fermentation, the cells were centrifuged at 4°C and 8000 rpm for 10 min to collect the wet cells. The wet cells were resuspended in 10 mM pH 7.0 potassium phosphate buffer and centrifuged again to collect the washed wet cells. 20 g of the washed wet cells were taken and resuspended in 100 mL of 10 mM pH 7.0 potassium phosphate buffer. The cells were then homogenized twice using a pressure homogenizer to obtain a homogenized bacterial solution. The bacterial solution was centrifuged at 8000 rpm for 30 min, and the supernatant was collected to obtain the enzyme solution containing the engineered transaminase mutant.

[0147] Example 11 Combinatorial Mutation of Mutants and Determination of Their Catalytic Performance

[0148] Weigh 10.0 g of sitagliptin precursor ketone and dissolve it in 30 mL of methanol. Stir thoroughly until completely dissolved to obtain the substrate stock solution. Weigh 1.49 g of triethanolamine and add pure water to 12.5 mL. Then add 5.9 g of isopropylamine, adjust the pH to 8.5 with concentrated hydrochloric acid, and then add pure water to make up the total volume to 40 mL to obtain the isopropylamine mixed stock solution.

[0149] Fix a 250 mL three-necked flask on a water bath, maintaining the water temperature at 45°C. Add the following to the three-necked flask sequentially: 17.5 mL of engineered transaminase mutant enzyme solution, 2 mM pyridoxal phosphate (PLP), and 7.5 mL of purified water. Slowly add the prepared isopropylamine mixture and stir until homogeneous. Adjust the pH of the reaction system to 8.5 using 4.0 M isopropylamine solution. Add 4.0 mL of the substrate stock solution to the three-necked flask to begin the reaction. Continuously add the remaining substrate stock solution to the three-necked flask using a peristaltic pump until all the substrate stock solution has been added.

[0150] During the reaction, the pH of the reaction system was continuously monitored and maintained at 8.5 ± 0.5 using 4.0 M isopropylamine solution. The total reaction time was 24 h. After the reaction, sitagliptin was extracted from the reaction system using isopropyl acetate. The organic phase was concentrated, and the solvent was evaporated to dryness to obtain approximately 8.5 g of sitagliptin. ee The purity is ≥99.9%. Dissolving 8.0 g of sitagliptin in an isopropanol-water solution, adding 85% phosphoric acid, and recrystallizing yields approximately 9.0 g of high-purity sitagliptin phosphate with a purity of 100.0%. ee Value ≥ 99.9%.

[0151] As can be seen from the above description, the embodiments of the present invention achieve the following technical effects:

[0152] 1. Significantly improved catalytic activity: The engineered transaminase mutant of the present invention exhibits significantly higher catalytic activity for sitagliptin precursor ketone than the wild-type enzyme and most existing engineered enzymes, enabling higher substrate conversion and product formation rates.

[0153] 2. High stereoselectivity: The engineered transaminase mutant of this invention can achieve extremely high enantiomeric excess ( ee The asymmetric synthesis of sitagliptin with a purity ≥ 99.9% directly meets the pharmacopoeia's stringent requirements for drug optical purity, avoiding subsequent complex and expensive chiral separation steps.

[0154] 3. Excellent thermal stability: The engineered transaminase mutant of the present invention has undergone directed evolution and can still maintain high activity and stability at high temperatures (e.g., 40℃-50℃, or even after heat treatment at 80℃), which is beneficial for temperature control and enzyme recycling in industrial production processes.

[0155] 4. Broad-spectrum organic solvent tolerance: The engineered transaminase mutant of the present invention has good tolerance to a variety of organic solvents, especially inexpensive alcohol solvents such as methanol, and can adapt to reaction systems containing high concentrations of organic solvents, thereby effectively solving the problem of poor substrate water solubility and significantly reducing production costs.

[0156] 5. Broad prospects for industrial application: The engineered transaminase mutant and its application method of this invention provide efficient, economical and environmentally friendly technical support for the large-scale industrial production of sitagliptin, and have broad market application prospects.

[0157] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A transaminase mutant, characterized in that, The transaminase mutants include: (a) A protein mutated from a wild-type transaminase, wherein the mutation is selected from mutations at any one or more of the following sites: F113, M52, V60, M85, G127, E115, F141, Q143, A160, T273, A275, P288, L56, D72, I117, or Y200, wherein the wild-type transaminase comprises the protein shown in SEQ ID NO: 1; or (b) A protein that has more than 70% identity with the amino acid sequence defined in (a) and has transaminase activity.

2. The transaminase mutant according to claim 1, characterized in that, In (a), the mutation is selected from any one or more of the following mutations: F113M, M52C, V60L, M85S, G127A, E115I, F141V, Q143C, A160F, T273S, A275L, P288M, L56I, D72F, I117T or Y200A, wherein the letter before the number represents the original amino acid and the letter after the number represents the mutated amino acid.

3. The transaminase mutant according to claim 1, characterized in that, The mutation includes any one of the following amino acid mutations: F113M, F113M+G127A, F113M+A160F, F113M+I117T+Y200A, L56I+D72F, I117T+Y200A, G127A+A160F, G127A+I117T+Y200A, A160F+I117T+Y200A, M52C, V60L, M85S, G127A, E115I, F141V, Q143C, A160F, T273S, A275L, P288M, L56I, D72F, I117T or Y200A.

4. A mutant library, characterized in that, The mutant library includes one or more of the following mutants: F113M, F113M+G127A, F113M+A160F, F113M+I117T+Y200A, L56I+D72F, I117T+Y20 0A, G127A+A160F, G127A+I117T+Y200A, A160F+I117T+Y200A, M52C, V60L, M85S, G 127A, E115I, F141V, Q143C, A160F, T273S, A275L, P288M, L56I, D72F, I117T or Y200A.

5. A DNA molecule, characterized in that, The DNA molecule encodes the transaminase mutant of any one of claims 1 to 3, or the mutant library of claim 4.

6. A recombinant plasmid, characterized in that, The recombinant plasmid contains the DNA molecule as described in claim 5.

7. The recombinant plasmid according to claim 6, characterized in that, The recombinant plasmid includes pET-28a.

8. A host cell, characterized in that, The host cell contains the DNA molecule of claim 5 or the recombinant plasmid of claim 6 or 7.

9. The host cell according to claim 8, characterized in that, The host cells include one or more of Escherichia coli, Bacillus subtilis, Pichia pastoris, or Saccharomyces cerevisiae.

10. A method for preparing sitagliptin, characterized in that, The preparation method includes: using the transaminase mutant of any one of claims 1 to 3, or the mutant library of claim 4, to perform an asymmetric aminotransfer reaction on sitagliptin precursor ketone to prepare sitagliptin.

11. The use of any one of the transaminase mutants of claims 1 to 3, the mutant library of claim 4, the DNA molecule of claim 5, the recombinant plasmid of claim 6 or 7, the host cell of claim 8 or 9, or the method for preparing sitagliptin of claim 10 in the synthesis of sitagliptin.

Citation Information

Patent Citations

  • Production method suitable for enzymatic synthesis of sitagliptin phosphate

    CN110791538A

  • An engineered transaminase polypeptide for preparing sitagliptin

    CN112048485B

  • Transaminase mutant and application thereof

    CN116240189A